Proton therapy developer Mevion Medical Systems is expanding its collaboration with Washington University in St. Louis to study Mevion's HyperScan pencil-beam scanning technology.
The two will look at how HyperScan affects the delivery of intensity-modulated proton therapy (IMPT) treatment delivery. They have entered into a master research agreement to expand their existing arrangement, which supports clinical education programs for proton therapy.
Washington University has also developed a multicenter proton patient registry and clinical education programs to benefit all proton therapy centers worldwide.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
